Author(s):
Rajamohamed H, Megha S, Mohankumar M, Lithish Kumar M K, Vishal Kesav T R, Sabarish Sachithanandan J, Yogesh V
Email(s):
yogeshvenkatesan77@gmail.com , rajahaithar@gmail.com
DOI:
10.52711/0974-360X.2026.00023 
Address:
Rajamohamed H1, Megha S1, Mohankumar M2, Lithish Kumar M K1, Vishal Kesav T R1, Sabarish Sachithanandan J1, Yogesh V1*
1Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu, India.
2Department of Pharmacy Practice, Arulmigu Kalasalingam College of Pharmacy, Krishnan Koil, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 1,
Year - 2026
ABSTRACT:
Background: An uncommon immune-mediated life-threatening reaction known as toxic epidermal necrolysis (TEN) is a severe form of Stevens-Johnson syndrome (SJS), with more than 30% involvement of body surface area (BSA). Various medications have been associated with causing SJS and TEN, including Allopurinol, Lamotrigine, Valproic acid, Sulfonamides, Minocycline antibiotics, Non-Steroidal Anti-inflammatory Drugs and medicines used in the treatment of HIV and tuberculosis. A recent study shows the elevated occurrence of SJS/TEN for the patients co-administered with Lamotrigine and Valproate. Around 45-year-oldfemale patient with a known case of seizure for the past 12 years was on Tab. Sodium valproate and Valproic acid 500mg BD. The patient had a family history of seizure. But her condition was worsened so Tab. Lamotrigine was added to her treatment regimen. Later, within a week, the patient experienced painful sores, blisters all over the upper surface of her body, H/O red raised lesions all over the body for one week, H/O fluid-filled lesions all over the body, and oral lesions for past three days and diagnosed as TEN. The main purpose for publishing this case report was to recommend the healthcare professionals to perform pre-treatment assessment, including genetic screening and careful consideration of the risk-benefit ratio, before initiating the therapy.
Cite this article:
Rajamohamed H, Megha S, Mohankumar M, Lithish Kumar M K, Vishal Kesav T R, Sabarish Sachithanandan J, Yogesh V. Lamotrigine - Induced Toxic Epidermal Necrosis: A Case Report with Review of the Literature. Research Journal of Pharmacy and Technology. 2026;19(1):147-2. doi: 10.52711/0974-360X.2026.00023
Cite(Electronic):
Rajamohamed H, Megha S, Mohankumar M, Lithish Kumar M K, Vishal Kesav T R, Sabarish Sachithanandan J, Yogesh V. Lamotrigine - Induced Toxic Epidermal Necrosis: A Case Report with Review of the Literature. Research Journal of Pharmacy and Technology. 2026;19(1):147-2. doi: 10.52711/0974-360X.2026.00023 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-1-23
REFERENCES:
1. Singh N, Phillips M. Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches. Skin Therapy Lett. 2022; Sep; 27(5): 7-13. PMID: 36469487.
2. Darshana Kumari Wankhede, Shalini Lokhande, Sonali Kolekar, Suvarna Gughare. Case report on Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). International Journal of Nursing Education and Research. 2024; 12(1): 67-0.
3. Mohammed Mustafa G, Chandana C, Feba Elizabeth Biju, Deepthi D J. A Case Report on Ciprofloxacin Induced SJS/TEN (Steven Johnson Syndrome/Toxic Epidermolysis Necrosis). Research Journal of Pharmacy and Technology. 2024; 17(6): 2707-9.
4. Marks ME, et al. Updates in SJS/TEN: collaboration, innovation, and community. Front Med (Lausanne). 2023; Oct 11; 10: 1213889. doi: 10.3389/fmed.2023.1213889. PMID: 37901413; PMCID: PMC10600400.
5. Vinod V. Bagilkar. Stevens - Johnson Syndrome / Toxic Epidermal Necrolysis in Pediatric . Int. J. Adv. Nur. Management 2015; 3(2): 155-160.
6. Zimmerman, D., and Dang, N. H. Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Immunologic reactions. In Oncologic Critical Care. 2020: 267–280.
7. Gronich, N., Maman, D., Stein, N. et al. Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study. Am J Clin Dermatol. 2022; 23: 257–266. https://doi.org/10.1007/s40257-021-00661-0
8. Prabhavalkar, K. S., Poovanpallil, N. B., and Bhatt, L. K . Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer. Frontiers in Pharmacology. 2015; 6. doi: https://doi.org/10.3389/fphar.2015.00242
9. Espinosa-Aguilar EJ, Piña-Ballantyne SA, Espinosa-Aguilar KL, Tun-Pisté JC, Calderón-Garcidueñas AL. Steven-Johnson Syndrome Induced by Lamotrigine and Valproic Acid in a Pediatric Patient: A Case Report. Cureus. 2023; 15(7): e41267. doi: 10.7759/cureus.41267. PMID: 37533620; PMCID: PMC10390704.
10. Reddy, S., and Puri, S. Lamotrigine-Induced Stevens–Johnson Syndrome: A Clinical Report. Ijcase reports and images.com. 2024; doi:11:101175Z01SR2020.
11. Ferrell, P. B., Jr, and McLeod, H. L. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics, 2008; 9(10): 1543–1546. doi: 10.2217/14622416.9.10.1543
12. HLA-B15:02 genotyping, carbamazepine hypersensitivity. Aruplab.com. Retrieved September. 18, 2024, from https://ltd.aruplab.com/Tests/Pub/2012049
13. Kwon, J. W., Park, J. W., and Kim, Y. S. HLA-B1502 and Lamotrigine-induced Severe Cutaneous Adverse Reactions. Allergy, Asthma and Immunology Research. 2013; 5(2): 110-112.
14. Remya Antony, Ashly Fernandez, Sandhya Lekshmi, Sreedevan Velayudhan, Sruthy Jose, Meenu Vijayan. Case report on Fluconazole Induced stevens - Johnson Syndrome. Research J. Pharm. and Tech. 2019; 12(8): 3735-3738.
15. Chung, W. H., Hung, S. I., et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature, 2004; 428(6982). 486.
16. Chen, P., Lin, J. J., et al. Carbamazepine-induced toxic effects and HLA-B1502 screening in Taiwan. New England Journal of Medicine. 2011; 364(12): 1126-1133.
17. Shaiji M J. Purple Glove Syndrome. Asian J. Nursing Education and Research. 2019; 9(4): 580-582.
18. Lim, K. S., Kwan, P., and Tan, C. T. Association of HLA-B1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurology Asia. 2008; 13: 15-21.
19. Zhou, Y., Krebs, K., Milani, L., and Lauschke, V. M. Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing. Clinical Pharmacology and Therapeutics. 2020; 109(1): 160–174.
20. Yakaiah Vangoori, Naga Vishnu Kandra, Praveen Kumar Uppala, U. Upendrarao, S.V. Saibaba, Murali Krishna Balijepalli, Butti Lavanya, SK. M. Shabana. Case Reports of Stevens Johnson Syndrome (SJS) Induced by Chemically Unrelated Drugs. Research Journal of Pharmacy and Technology. 2023; 16(5): 2415-8.
21. Methaneethorn, J., and Leelakanok, N. Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses. Seizure: The Journal of the British Epilepsy Association. 2020; 82: 133–147.
22. Milosheska, D., Lorber, B., Vovk, T., Kastelic, M., Dolžan, V., and Grabnar, I. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. British Journal of Clinical Pharmacology. 2016; 82(2): 399–411.
23. Mohathasim Billah A, Rajamohamed H, Mohamed Akram Ali S, Porkodi M, Vikashini S, Lida Sajimon. Statin-induced Rhabdomyolysis and its Management – A Case Report. Research Journal of Pharmacy and Technology. 2024; 17(7): 3241-5.
24. Yang, J., Wang, J., Ning, L., Wu, C., Liu, Y., Xia, J., Guan, Y., Liu, Q., and Zheng, J. Influence of UGT2B7, UGT1A4 and ABCG2 polymorphisms on the pharmacokinetics and therapeutic efficacy of lamotrigine in patients with epilepsy. European Journal of Drug Metabolism and Pharmacokinetics. 2024; 49(4): 437–447.
25. Zhang L, Lavoie J, Annis K, et al. Glucuronidation of lamotrigine by UGT1A4 and UGT2B7. Biochem Pharmacol. 2007; 74(10): 1441-9. doi:10.1016/j.bcp.2007.07.005.
26. Dobry, A. S., Himed, S., Waters, M., and Kaffenberger, B. H. Scoring assessments in Stevens-Johnson syndrome and toxic epidermal necrolysis. Frontiers in Medicine. 2022; 9. https://doi.org/10.3389/fmed.2022.883121
27. Abdullahi Rabiu Abubakar, Nordin Bin Simbak, Mainul Haque. Adverse Drug Reactions: Predisposing Factors, Modern Classifications and Causality Assessment. Research J. Pharm. and Tech. 2014; 7(9): 1091-1098.
28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Updated 2019 May 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548069/
29. Frantz, R., Huang, S., Are, A., and Motaparthi, K. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A review of diagnosis and management. Medicina (Kaunas, Lithuania), 2021; 57(9): 895. https://doi.org/10.3390/medicina57090895
30. Al-Shaqsi, S. Important Points in Toxic Epidermal Necrolysis Management. Oman Medical Journal. 2019; 34(4): 357–358. https://doi.org/10.5001/omj.2019.70
31. Toxic epidermal necrolysis (TEN). Cleveland Clinic. Retrieved July 15, 2024, from https://my.clevelandclinic.org/health/diseases/21616-toxic-epidermal-necrolysis-ten
32. Samantha P Jellinek-Cohen. Toxic epidermal necrolysis (TEN) clinical presentation. Medscape. Accessed on 05 october 2024. https://emedicine.medscape.com/article/229698-clinical
33. Estrella-Alonso, A., Aramburu, J. A., González-Ruiz, M. Y., Cachafeiro, L., Sánchez Sánchez, M., and Lorente, J. A. Toxic epidermal necrolysis: a paradigm of critical illness. Revista Brasileira de Terapia Intensiva. 2017; 29(4): 499. https://doi.org/10.5935/0103-507x.20170075
34. Oflaz, S., Kalkan, H. S., Gokce, E., Karsidag, C., and Gurel, M. S. Stevens Johnson syndrome—toxic epidermal necrolysis induced by A combination of lamotrigine and valproic acid: A case report. Klinik Psikofarmakoloji Bulteni [Bulletin of Clinical Psychopharmacology]. 2011; 21(2): 150–153. https://doi.org/10.5455/bcp.20110410031809
35. Dobry, A. S., Himed, S., Waters, M., and Kaffenberger, B. H. Scoring assessments in Stevens-Johnson syndrome and toxic epidermal necrolysis. Frontiers in Medicine. 2022; 9: 883121. https://doi.org/10.3389/fmed.2022.883121
36. Nimmy P S, Greeshma V R, Aiswaria S Pal. Lennox- Gastaut Syndrome (Childhood Epileptic Encephalopathy) – A Rare Case Report. International Journal of Nursing Education and Research. 2024; 12(3): 212-4.
37. N. Sangeetha, U.S. Mahadeva Rao.Hepatotoxic Effect of Sodium Valproate Therapy in Epileptic Children. Research J. Pharma. Dosage Forms and Tech. 2011; 3(4): 135-138.